These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28720537)

  • 21. Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.
    Jong T; Li J; Morton DA; Zhou QT; Larson I
    J Pharm Sci; 2016 Mar; 105(3):1156-63. PubMed ID: 26886330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.
    Mangal S; Nie H; Xu R; Guo R; Cavallaro A; Zemlyanov D; Zhou QT
    Pharm Res; 2018 Jan; 35(2):28. PubMed ID: 29374368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ; Worth Longest P; Hindle M
    Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance.
    Yang Y; Yang Z; Ren Y; Mei X
    Drug Deliv; 2014 Sep; 21(6):480-6. PubMed ID: 24491208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
    Eedara BB; Rangnekar B; Doyle C; Cavallaro A; Das SC
    Int J Pharm; 2018 May; 542(1-2):72-81. PubMed ID: 29524618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of formulation and inhaler parameters on the dispersion of spray freeze dried voriconazole particles.
    Liao Q; Lam ICH; Lin HHS; Wan LTL; Lo JCK; Tai W; Kwok PCL; Lam JKW
    Int J Pharm; 2020 Jun; 584():119444. PubMed ID: 32445908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome.
    Boc S; Momin MAM; Farkas DR; Longest W; Hindle M
    AAPS PharmSciTech; 2021 Apr; 22(4):136. PubMed ID: 33860409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
    Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
    J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
    Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
    Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin.
    Barazesh A; Gilani K; Rouini M; Barghi MA
    Daru; 2020 Jun; 28(1):75-85. PubMed ID: 31808069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
    Momin MAM; Sinha S; Tucker IG; Das SC
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.
    Liang W; Chow MY; Lau PN; Zhou QT; Kwok PC; Leung GP; Mason AJ; Chan HK; Poon LL; Lam JK
    Mol Pharm; 2015 Mar; 12(3):910-21. PubMed ID: 25599953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of thermal and shear stresses in the spray drying process on the stability of siRNA dry powders.
    Wu J; Wu L; Wan F; Rantanen J; Cun D; Yang M
    Int J Pharm; 2019 Jul; 566():32-39. PubMed ID: 31077763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation.
    Arte KS; Tower CW; Mutukuri TT; Chen Y; Patel SM; Munson EJ; Tony Zhou Q
    Int J Pharm; 2024 Jan; 650():123698. PubMed ID: 38081559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.